Provisions governing hospital reimbursement for biological products to treat rare diseases modified.
Introduction and first reading, referred to
Email me when HF 4349 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HF 4349. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill changes Minnesota law so hospitals get a distinct payment for biological products used in inpatient cell or gene therapy that treat rare diseases. The payment must equal the hospital’s actual acquisition cost, and it applies only when the drug maker has a value‑based agreement with the state commissioner. This aims to ensure hospitals are not financially penalized for providing these high‑cost therapies.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HF 4349
3 free questions a day, no accountHearings
- Health Finance and PolicyHealth Finance and Policy · Mar 23, 2026
History
- Introduction and first reading, referred to Health Finance and Policy
Sponsors
- Bierman · sponsor
- Bahner
- Huot
- Mahamoud
- Reyer
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HF 4349 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HF 4349 freeOr ask your AI assistant about HF 4349 directly:
Add to Claude, ChatGPT or Cursor